По вашему запросу найдено документов: 40

Страница 1 из 4

Exosomal miRNA-146a is downregulated in clear cell renal cell carcinoma patients with severe immune-related adverse events
Ivanova, E., Asadullina, D., Rakhimov, R., Izmailov, A., Izmailov, Al., Gilyazova, G., Galimov, Sh., Pavlov, V., Khusnutdinova, E., Gilyazova, I. (2022)
related toxicity. Immune-related adverse events (irAEs) are a major cause of immune checkpoint inhibitors
МЕСТНАЯ И ОБЩАЯ РЕАКЦИИ ПРИ ВВЕДЕНИИ ВАКЦИНЫ ПРОТИВ COVID-19
LOCAL AND SYSTEMIC ADVERSE REACTIONS FOLLOWING COVID-19 VACCINE
Zherebtsova, N.Yu., Kajdanek, T.V., Жеребцова, Н.Ю., Кайданек, Т.В. (2022)
LOCAL AND SYSTEMIC ADVERSE REACTIONS FOLLOWING COVID-19 VACCINE
ЭФФЕКТИВНОСТЬ ИНГИБИТОРА ТИРОЗИНКИНАЗ 1-ГО ПОКОЛЕНИЯ (СУНИТИНИБ) В ТЕРАПИИ МЕТАСТАТИЧЕСКОГО ПОЧЕЧНО-КЛЕТОЧНОГО РАКА В АЛЬТЕРНАТИВНЫХ РЕЖИМАХ ДОЗИРОВАНИЯ
EFFICACY OF THE 1ST GENERATION TYROSINE KINASE INHIBITOR SUNITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ALTERNATIVE DOSING REGIMENS
МЕНЬШИКОВ, К. В., СУЛТАНБАЕВ, А. В., МУСИН, Ш. И., ИЗМАЙЛОВ, А. A., ЧАЛОВ, В. С., МЕНЬШИКОВА, И. А., СУЛТАНБАЕВА, Н. И., ПОПОВА, Е. В., ЛИПАТОВ, Д. О., MENSHIKOV, K. V., SULTANBAEV, A. V., MUSIN, SH. I., IZMAILOV, A. A., CHALOV, V. S., MENSHIKOVA, I. A., SULTANBAEVA, N. I., POPOVA, E. V., LIPATOV, D. O. (2022)
ADVERSE EVENTS
Адаптация и валидация шкалы непереносимости метотрексата MISS у детей с ювенильным идиопатическим артритом: одномоментное поперечное исследование
Customization and validation of the Methotrexate Intolerance Severity Score in children with juvenile idiopathic arthritis: a cross-sectional study
Жуков, С.С., Малиевский, В.А., Леонова, А.С., Zhukov, S.S., Malievskiy, V.A., Leonova, A.S. (2022)
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit, Rebecca, Lisyanskaya, Alla, Fedenko, Alexander, Dvorkin, Mikhail, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, Oza, Amit M (2022)
·0017). Most treatment-emergent adverse events were grade 1 or 2. The most common grade 3 or worse treatment
ASSESSING INDEX OF ACCUMULATED CYTOGENETIC DISORDERS IN WORKERS EMPLOYED IN METALLURGY UNDER EXPOSURE TO ADVERSE OCCUPAITONAL FACTORS
Vlasova, N.V., Masyagutova, L.M., Abdrakhmanova, E.R., Rafikova, L.A., Chudnovets, G.M. (2022)
exposure to adverse occupational factors. A clinical and diagnostic examination of workers employed at a
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Onorato, Eustaquio Maria, Onorato, Eustaquio Maria, Muratori, Manuela, Smolka, Grzegorz, Wojakowski, Wojtek, Pysz, Piotr, Zorinas, Aleksejus, Zakarkaite, Diana, Eltchaninoff, Hélène, Litzer, Pierre-Yves, Godart, François, Calvert, Patrick, Christou, Christos, Mussayev, Abdurashid, Missiroli, Bindo, Buzaev, Igor, Curello, Salvatore, Tesorio, Tullio, Bartorelli, Antonio Luca (2022)
. In total, 35 serious adverse events (SAEs) were reported in 27 patients (19.7%) of the SAF population
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Deal, C, Steelman, J, Vlachopapadopoulou, E, Stawerska, R, Silverman, LA;, Phillip, M, Kim, HS, Ko, CW, Malievskiy, O, Cara, JF, Roland, CL, Taylor, CT, Valluri, SR, Wajnrajch, MP, Pastrak, A, Miller, BS (2022)
experiencing mild to moderate treatment-emergent adverse events in both groups (somatrogon: 78.9%, somatropin
Safety, Efficacy and Long-Term Outcomes of Patients Treated with the Occlutech Paravalvular Leak Device for Significant Paravalvular Regurgitation
Onorato, EM, Alamanni, F, Muratori, M, Smolka, G, Wojakowski, W, Pysz, P, Zorinas, A, Zakarkaite, D, Eltchaninoff, H, Litzer, PY, Godart, F, Calvert, P, Christou, C, Mussayev, A, Missiroli, B, Buzaev, I, Curello, S, Tesorio, T, Bartorelli, AL (2022)
, respectively. In total, 35 serious adverse events (SAEs) were reported in 27 patients (19.7%) of the SAF
Influence of alcohol on prenatal development of the foetus
Зиганшин, А. М., Ящук, А. Г., Мулюков, А. Р., Омаров, М. А., Хисамова, Н. Р., Ziganshin, A. M., Yashchuk, A.G., Mulykov, A.R., Omarov, M.A., Khisamova, N.R. (2022)

Страница 1 из 4

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год